Dr. Ming Lu 陆明
Chief Physician, Associate Professor
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and comprehensive treatment of digestive system tumors, including gastric, colorectal, neuroendocrine, esophageal, pancreatic, and biliary tract cancers.
Dr. Lu holds a PhD from Peking University Cancer Hospital and serves as Associate Professor and Master’s Supervisor. With nearly 20 years of experience in diagnosing and treating digestive system malignancies, Dr. Lu focuses on individualized and comprehensive care for complex cases involving neuroendocrine, gastric, colorectal, esophageal, and pancreatic cancers.
Professional roles
- Member and Secretary-General, Multidisciplinary Treatment (MDT) Study Group, Chinese Medical Doctor Association
- Secretary-General, China Tumor MDT Alliance
- Member, Expert Committee on Rational Drug Use for Digestive System Tumors, National Health Commission
- Standing Committee Member, Neuroendocrine Tumor Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Lu Ming). Papers usually list the name as Ming Lu or Lu M.
Selected publications
97 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Cancer, 2026 (senior author): Surufatinib combined with sintilimab and IBI310 for the treatment of high-grade advanced-neuroendocrine neoplasms: A single arm, open-label, single-center, phase II study. PubMed 41460043
- EClinicalMedicine, 2025 (senior author): Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. PubMed 41209655
- Chemistry, 2025 (senior author): Synergistic Enhancement Mechanisms of Lithium-Ion Storage in Black Phosphorus@Ti(3)C(2)T(x) (BP@Ti(3)C(2)T(x)) Composite Thin-Film Electrodes. PubMed 40525988
- EClinicalMedicine, 2025 (senior author): Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study. PubMed 40521168
- Chin J Cancer Res, 2024 (senior author): Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas. PubMed 38455367
- Neuroendocrinology, 2022 (senior author): Serum Biomarker Status with a Distinctive Pattern in Prognosis of Gastroenteropancreatic Neuroendocrine Carcinoma. PubMed 34592743
- Cancer Med, 2021 (senior author): Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine-non-neuroendocrine neoplasm. PubMed 34109756
- Cancer Commun (Lond), 2020 (senior author): Favorable response to immunotherapy in a pancreatic neuroendocrine tumor with temozolomide-induced high tumor mutational burden. PubMed 33230973
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion